1. Prevalence, patterns and determinants of dyslipidaemia among South African adults with comorbidities.
- Author
-
Masilela C, Adeniyi OV, and Benjeddou M
- Subjects
- Adolescent, Adult, Aged, Biomarkers blood, Cross-Sectional Studies, Diabetes Mellitus ethnology, Dyslipidemias blood, Dyslipidemias diagnosis, Dyslipidemias drug therapy, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Male, Middle Aged, Multimorbidity, Obesity ethnology, Prevalence, Race Factors, Risk Assessment, Risk Factors, Sex Factors, South Africa epidemiology, Young Adult, Black People, Dyslipidemias ethnology, Lipids blood
- Abstract
The present study assessed the prevalence, patterns and determinants of dyslipidaemia among South African adults with multi-morbidities. In this study, 614 individuals with DM and hypertension were recruited. Dyslipidaemia was defined as elevated levels of total cholesterol (TC) ≥ 5.2 mmol/L and/or low-density lipoprotein cholesterol (LDL-C) ≥ 2.6 mmol/L, triglycerides (TG) ≥ 1.8 mmol/L and low high-density lipoprotein cholesterol (HDL-C) < 1 mmol/L for men and < 1.2 mmol/L for women. Multivariate regression model (adjusted) analysis was used to identify the significant determinants of dyslipidaemia. The prevalence of dyslipidaemia was 76.7% (n = 471), with females showing the highest prevalence 357 (75.79%). Elevated TG (62.21%) was the most prevalent form of dyslipidemia. Only 103 (16.77%) participants were on statin therapy. The multivariate logistic regression model analysis (adjusted) showed that, the Zulu ethnicity (AOR = 2.45; 95%CI 1.48-4.05) was associated with high TC. DM (AOR = 2.00; 95%CI 1.30-3.06) and the female sex (AOR = 2.54; 95%CI 1.56-4.12) were associated with low HDL-C. Obesity (AOR = 1.57; 95%CI 1.12-2.21) and the Zulu ethnicity (AOR = 1.60; 95%CI 1.00-2.54) were associated with elevated LDL-C. DM (AOR = 2.32; 95%CI 1.61-3.34) was associated with elevated TG. We found a high prevalence of dyslipidaemia. The study further demonstrated that prevention and treatment of dyslipidaemia should be prioritised among individuals with multi-morbidities., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF